Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results

continues to pursue

development of SNS-595 in acute myeloid leukemia (AML). A Phase 1b

clinical trial of SNS-595 in combination with cytarabine in relapsed

or refractory AML patients is in progress. Sunesis plans to begin

enrollment in a Phase 2 clinical trial of SNS-595 on a weekly dose

schedule in previously untreated elderly AML patients in the first

half of 2008. Sunesis expects to report data later this year for

both AML clinical trials.

-- Results from a non-clinical study of SNS-032, a potent and selective

inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9, were presented

at ASH. These data demonstrated that SNS-032 induces apoptosis in

chronic lymphocytic leukemia (CLL) cells. Furthermore, SNS-032's in

vitro activity compared favorably with flavopiridol in CLL cells

obtained from patients. SNS-032 currently is in a Phase 1 clinical

trial of patients with relapsed or refractory CLL or multiple myeloma.

To date, the drug has been well tolerated in this trial, and dose

escalation in both indications is expected to be completed this year.

-- Sunesis is continuing enrollment in its Phase 1 dose-escalating trial

of SNS-314, a potent and selective inhibitor of Aurora kinases A, B and

C, in advanced solid tumors. To date, SNS-314 has been well tolerated

and no dose-limiting toxicities have been observed. The company

expects to identify a maximum-tolerated dose in this Phase 1 clinical

trial this year.

-- In December, Sunesis and the Multiple Myeloma Research Consortium

(MMRC) announced a collaboration to evaluate the preclinical activity

of SNS-032 in multiple myeloma-relevant models and in primary disease

tissue, extending non-clinical studies performed by Sunesis.

-- In February 2008, Sunesis received

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
(Date:7/28/2014)... 2014 According to ... (Consumables, Instruments, Services), Methods (Phenotypic, Genotypic), Applications (Pharmaceutical, Diagnostic, ... Characterization) - Global Forecasts to 2019" published ... estimated at $896.5 Million in 2014 and ... 2019, growing at a CAGR of 5.9% ...
(Date:7/28/2014)... , July 28, 2014   Propeller Health , ... announced the hire of Brad Towle as ... be responsible for driving the company,s sales growth, customer ... in healthcare, and specifically his past role in the ... the company at this pivotal time in the industry," ...
(Date:7/28/2014)... The global market for biotechnology is expected ... a new study by Grand View Research, Inc. Increasing ... vaccines and drugs in an attempt to improve healthcare ... to drive market demand over the next six years. ... the use of genetically engineered seeds is expected to ...
(Date:7/28/2014)... Research and Markets has announced the ... report to their offering. ... technique used to determine the size of a particle in ... to analyze the size of particles as it can affect ... performed to determine the behavior and nature of a material, ...
Breaking Biology Technology:Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Global Particle Size Analysis Market 2014-2018 2
... , , ... Tobira Therapeutics Inc., a clinical stage biotechnology company committed ... life-threatening and life-altering infectious diseases, today announced pharmacokinetic data ... of TBR-652 in sixty healthy volunteers. TBR-652, a ...
... CAMBRIDGE, Mass., Sept. 14 Ironwood Pharmaceuticals, Inc. today ... officer and senior vice president of marketing and sales. Mr. McCourt ... lead Ironwood,s growing marketing and sales team. , , ... , Mr. McCourt comes to Ironwood from Amgen, where ...
... , , , JOHNSON CITY, ... Rx100, a potent radioprotectant as well as radiomitigator, protects against lethal, ... after exposure. , , In recent experiments, ... subcutaneous dose at either 48 or 72 hours after lethal, whole-body ...
Cached Biology Technology:Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV 2Ironwood Appoints Thomas McCourt As Chief Commercial Officer and Senior Vice President of Marketing and Sales 2Rx100 Rescues Life if Administered Up to 72 Hours After Exposure to Lethal, Whole-Body Radiation! 2
(Date:7/28/2014)... 28, 2014)The Brain & Behavior Research Foundation today ... Freedman Prizes, recognizing exceptional clinical and basic research ... NARSAD Young Investigator Grants. The grants enable early ... and psychosocial research for the prevention, early detection, ... one in four people. , Six young scientistswinners ...
(Date:7/28/2014)... Inspired Engineering at Harvard University today announced that ... a newly formed private company to accelerate development ... The announcement follows a worldwide license ... and the start-up Emulate Inc., relating to the ... , "This is a big win towards ...
(Date:7/27/2014)... one of the largest prevalence studies to date, researchers ... prevalence estimates for the hepatitis C virus (HCV). Findings ... for the Study of Liver Diseases, indicate that genotype ... million patients infected of which one-third reside in East ... is the next most prevalent, followed by genotypes 2, ...
Breaking Biology News(10 mins):The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Hepatitis C virus genotype 1 is most prevalent worldwide 2
... Ind. - As the United Nations climate negotiations proceed ... toward quantifying the "socioclimatic" exposure of different countries to ... University and the Abdus Salam International Centre for Theoretical ... the United States - major greenhouse gas-emitting nations that ...
... $50 billion in manufactured goods last year, according to ... $2.6 trillion. By 2011, over $15 billion in nano-enabled ... $3 billion in 2006. And industry experts project that ... consumer food products by 2010. Yet, ...
... from the Early Jurassic has been discovered in Antarctica. ... hammeri and lived about 190 million years ago. , ... based on partial foot, leg and ankle bones found ... at an elevation of more than 13,000 feet. , ...
Cached Biology News:Scientists develop new measure of 'socioclimactic' risk 2Scientists develop new measure of 'socioclimactic' risk 3Scientists develop new measure of 'socioclimactic' risk 4FDLI, PEN co-sponsor major conference on nanotechnology 2FDLI, PEN co-sponsor major conference on nanotechnology 3Massive dinosaur discovered in Antarctica sheds light on life, distribution of sauropodomorphs 2
2'-Fluorine-CTP (2'-F-CTP) is readily incorporated into transcripts by T7 and SP6 R&DNA™ Polymerase and is available separately....
... J. Karn (1995) This volume ... and methods for the study of major ... reverse transcriptase, ribonuclease H, integrase and protease. ... binding assays; Tat and Rev assays; HIV/CD4 ...
Human Glypican 2 Biotinylated Affinity Purified PAb...
Human Contactin-2/TAG1 Affinity Purified Polyclonal Ab...
Biology Products: